Navenibart not checked
Astria Therapeutics, Inc. · STAR-0215
FollowEvery change as it happens, and a Monday email
Trials
4 active
6 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
- How it’s given
- “Navenibart will be administered as a subcutaneous injection.”In the company’s words, NCT06842823 on ClinicalTrials.gov
- Tested for
- Hereditary Angioedema (HAE) (2 trials), Hereditary Angioedema
- Main trialPhase 3
- “This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.”In the company’s words, NCT06842823 on ClinicalTrials.gov
- Other names
- STAR-0215 · Autoinjector
Other drugs for Hereditary Angioedema (HAE)
- DonidalorsenIonis Pharmaceuticals, Inc. · Phase 3
- DeucrictibantPharvaris Netherlands B.V. · Phase 3
- ADX-324ADARx Pharmaceuticals, Inc. · Phase 3
- BerotralstatBioCryst Pharmaceuticals · Phase 3
- NTLA-2002Intellia Therapeutics · Phase 3
- BW-20805Shanghai Argo Biopharmaceutical Co., Ltd. · Phase 2
Coming up3
- DecPhase 3 trial completes · ClinicalTrials.gov
- Mar 2031Phase 2 trial completes · ClinicalTrials.gov
- Jun 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2026 | A Study of Navenibart in Participants With Hereditary Angioedema | |
| Phase 3Enrolling by invitation | Jun 2031 | A Long-Term Study of Navenibart in Participants With Hereditary Angioedema | |
| Phase 2Active, not recruiting | Mar 2031 | A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema | |
| Phase 1Recruiting | Sep 2026 | A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants | |
| Phase 1/2Completed | 13 Mar 2025 | A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema | |
| Phase 1Completed | 17 Nov 2023 | A Study of STAR-0215 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026